Ir para o conteúdo principal

United States Últimas notícias

Todas as matérias desta categoria, das mais recentes às mais antigas.

Grafa

Genmab’s Rina-S combination shows manageable safety in ovarian cancer trial

Genmab (NASDAQ:GMAB) presented new data at the 2026 Society of Gynecologic Oncology (SGO) Annual Meeting on Monday, demonstrating that its investigational antibody-drug conjugate (ADC), rinatabart sesutecan (Rina-S), can be safely combined with bevacizumab in patients with advanced ovarian cancer.

Leia mais: Genmab’s Rina-S combination shows manageable safety in ovarian cancer trial